このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Arrowhead Pharmaceuticals 将来の成長
Future 基準チェック /26
Arrowhead Pharmaceuticalsは、23.4%と51.5%でそれぞれ年率23.4%で利益と収益が成長すると予測される一方、EPSはgrowで24.8%年率。
主要情報
21.0%
収益成長率
23.0%
EPS成長率
Biotechs 収益成長 | 28.2% |
収益成長率 | 52.9% |
将来の株主資本利益率 | n/a |
アナリストカバレッジ | Good |
最終更新日 | 10 Sep 2024 |
今後の成長に関する最新情報
Recent updates
Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
9/30/2026 | 231 | -456 | -546 | -311 | 10 |
9/30/2025 | 151 | -504 | -444 | -338 | 16 |
9/30/2024 | 62 | -537 | -617 | -479 | 16 |
6/30/2024 | 20 | -539 | -533 | -352 | N/A |
3/31/2024 | 35 | -471 | -470 | -257 | N/A |
12/31/2023 | 182 | -297 | -403 | -196 | N/A |
9/30/2023 | 241 | -205 | -331 | -154 | N/A |
6/30/2023 | 256 | -181 | -342 | -197 | N/A |
3/31/2023 | 273 | -150 | -353 | -245 | N/A |
12/31/2022 | 278 | -155 | -236 | -150 | N/A |
9/30/2022 | 243 | -176 | -189 | -136 | N/A |
6/30/2022 | 250 | -154 | -120 | -91 | N/A |
3/31/2022 | 263 | -112 | -75 | -52 | N/A |
12/31/2021 | 144 | -183 | 124 | 149 | N/A |
9/30/2021 | 138 | -141 | 148 | 171 | N/A |
6/30/2021 | 108 | -126 | 167 | 184 | N/A |
3/31/2021 | 89 | -110 | 165 | 181 | N/A |
12/31/2020 | 80 | -103 | -123 | -111 | N/A |
9/30/2020 | 88 | -85 | -108 | -96 | N/A |
6/30/2020 | 124 | -24 | -89 | -71 | N/A |
3/31/2020 | 139 | 10 | -46 | -27 | N/A |
12/31/2019 | 164 | 53 | -34 | -19 | N/A |
9/30/2019 | 169 | 68 | 161 | 173 | N/A |
6/30/2019 | 137 | 46 | 152 | 157 | N/A |
3/31/2019 | 95 | 10 | 130 | 132 | N/A |
12/31/2018 | 47 | -29 | 134 | 136 | N/A |
9/30/2018 | 16 | -54 | -49 | -47 | N/A |
6/30/2018 | 14 | -54 | -55 | -54 | N/A |
3/31/2018 | 22 | -44 | N/A | -50 | N/A |
12/31/2017 | 31 | -35 | N/A | -49 | N/A |
9/30/2017 | 31 | -34 | N/A | -24 | N/A |
6/30/2017 | 23 | -46 | N/A | -25 | N/A |
3/31/2017 | 13 | -60 | N/A | -33 | N/A |
12/31/2016 | 4 | -75 | N/A | -33 | N/A |
9/30/2016 | 0 | -82 | N/A | -64 | N/A |
6/30/2016 | 0 | -84 | N/A | -66 | N/A |
3/31/2016 | 0 | -81 | N/A | -61 | N/A |
12/31/2015 | 0 | -89 | N/A | -63 | N/A |
9/30/2015 | 0 | -92 | N/A | -66 | N/A |
6/30/2015 | 0 | -90 | N/A | -65 | N/A |
3/31/2015 | 0 | -85 | N/A | -61 | N/A |
12/31/2014 | 0 | -71 | N/A | -53 | N/A |
9/30/2014 | 0 | -59 | N/A | -35 | N/A |
6/30/2014 | 0 | -50 | N/A | -30 | N/A |
3/31/2014 | 0 | -44 | N/A | -25 | N/A |
12/31/2013 | 0 | -37 | N/A | -22 | N/A |
9/30/2013 | 0 | -31 | N/A | -19 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: ARWR今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: ARWR今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: ARWR今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: ARWRの収益 ( 50.6% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: ARWRの収益 ( 50.6% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: ARWRの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です